Drug discovery: new models for industry–academic partnerships

Tralau-Stewart, Cathy; Wyatt, Colin A.; Kleyn, Dominique; Ayad, Alex

doi:10.1016/j.drudis.2008.10.003

Cited by 115 publications

(86 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The initiative seeks to improve collaboration between industry and academia, which has been identifi ed as a potential way forward for some years. 334 40 projects are in motion that cover many areas of medicine including antibiotic resistance (eg, COMBACTE and PreDICT-TB). Further Innovative Medicines Initiative funds will be targeted at antibiotic drug discovery in the New Drugs for Bad Bugs programme, if these funds were to be available at early stages of antibiotic discovery that could have a substantial eff ect.…”

Section: Pharmaceutical Industry Collaborationmentioning

confidence: 99%

Antibiotic resistance—the need for global solutions

Laxminarayan

Dusé

Wattal

et al. 2013

The Lancet Infectious Diseases

3,494

2,602

View full text Add to dashboard Cite

The causes of antibiotic resistance are complex and include human behaviour at many levels of society; the consequences aff ect everybody in the world. Similarities with climate change are evident. Many eff orts have been made to describe the many diff erent facets of antibiotic resistance and the interventions needed to meet the challenge. However, coordinated action is largely absent, especially at the political level, both nationally and internationally. Antibiotics paved the way for unprecedented medical and societal developments, and are today indispensible in all health systems. Achievements in modern medicine, such as major surgery, organ transplantation, treatment of preterm babies, and cancer chemotherapy, which we today take for granted, would not be possible without access to eff ective treatment for bacterial infections. Within just a few years, we might be faced with dire setbacks, medically, socially, and economically, unless real and unprecedented global coordinated actions are immediately taken. Here, we describe the global situation of antibiotic resistance, its major causes and consequences, and identify key areas in which action is urgently needed.

show abstract

Section: Pharmaceutical Industry Collaborationmentioning

confidence: 99%

Antibiotic resistance—the need for global solutions

Laxminarayan

Dusé

Wattal

et al. 2013

The Lancet Infectious Diseases

3,494

2,602

View full text Add to dashboard Cite

show abstract

“…However, there are several significant public-private collaborations in funding academic research. For instance, the Broad Institute in Cambridge, MA is a partnership between the Massachusetts Institute of Technology, Harvard University and its hospitals, and the Whitehead Institute for Biomedical Research, and has been funded by charitable donations, the Novartis Diabetes Initiative, and the RNAi consortium (14). Such partnerships are still early in their life cycle and will require continued effort to become an efficient method of bringing new medicines to market.…”

Section: Industry Backgroundmentioning

confidence: 99%

New Financing Methods in the Biopharma Industry: A Case Study of Royalty Pharma, Inc.

Naraharisetti

2013

SSRN Journal

View full text Add to dashboard Cite

The biotechnology and pharmaceutical industries are facing significant challenges to their existing business models because of expiring drug patents, declining risk tolerance of venture capitalists and other investors, and increasing complexity in translational medicine. In response to these challenges, new alternative investment companies have emerged to bridge the biopharma funding gap by purchasing economic interests in drug royalty streams. Such purchases allow universities and biopharma companies to monetize their intellectual property, creating greater financial flexibility for them while giving investors an opportunity to participate in the life sciences industry at lower risk. Royalty Pharma is the largest of these drug royalty investment companies, and in this case study, we profile its business model and show how its unique financing structure greatly enhances the impact it has had on the biopharma industry and biomedical innovation.

show abstract

“…However, we should not underestimate cultural barriers or the complications associated with managing intellectual property, two aspects that have historically hampered interaction between academia and industry ( 48 ). To overcome these long-standing barriers between academia and industry, we must be creative and innovative in the way we use current business models in drug discovery and development as well as the way we envisage collaborations ( 49 ). Several models have been proposed, including collaborations in the precompetitive stage, in which tools developed by a consortium are freely available to members, and collaborations at the discovery stage (50)(51)(52).…”

Section: Academia-industry Partnerships: a Path Forwardmentioning

confidence: 99%

Oncology Drug Discovery: Planning a Turnaround

et al. 2014

View full text Add to dashboard Cite

Summary:We have made remarkable progress in our understanding of the pathophysiology of cancer. This improved understanding has resulted in increasingly effective targeted therapies that are better tolerated than conventional cytotoxic agents and even curative in some patients. Unfortunately, the success rate of drug approval has been limited, and therapeutic improvements have been marginal, with too few exceptions. In this article, we review the current approach to oncology drug discovery and development, identify areas in need of improvement, and propose strategies to improve patient outcomes. We also suggest future directions that may improve the quality of preclinical and early clinical drug evaluation, which could lead to higher approval rates of anticancer drugs. Cancer Discov;4(4);[397][398][399][400][401][402][403][404]

show abstract

Drug discovery: new models for industry–academic partnerships

Cited by 115 publications

References 16 publications

Antibiotic resistance—the need for global solutions

Antibiotic resistance—the need for global solutions

New Financing Methods in the Biopharma Industry: A Case Study of Royalty Pharma, Inc.

Oncology Drug Discovery: Planning a Turnaround

Contact Info

Product

Resources

About